Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659269 · ClinicalTrials.gov registry record · Phase 3
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
A Phase 3 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 3
- Development phase
- 319
- Enrollment target
NCT00659269 is a Phase 3 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 319 participants.
The verdict
NCT00659269, a Phase 3 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 319 participants
- Enrollment target
Study Summary
Many types of chemotherapy may cause nerve damage as a side effect. This neurotoxicity can manifest as peripheral sensory neuropathy (characterized by numbness, tingling, or pain). The goal of this study is to determine the efficacy of the combination of vitamin B6 and B12 in preventing chemotherapy induced neuropathy.
Interventions
- DRUG Chemotherapy
- DIETARY_SUPPLEMENT Multivitamin (MV)
- DIETARY_SUPPLEMENT Multivitamin + Vitamin B12 + Vitamin B6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2006-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659269
The ClinicalTrials.gov registry entry for NCT00659269 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Chemotherapy is the first listed.
NCT00659269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659269 about?
NCT00659269 is a clinical study titled "A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients". Many types of chemotherapy may cause nerve damage as a side effect. This neurotoxicity can manifest as peripheral sensory neuropathy (characterized by numbness, tingling, or pain). The goal of this study is to determine the efficacy of the combination of vitamin B6 and B12 in preventing chemotherapy...
What is the current status of trial NCT00659269?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 319 participants. The study started on 2006-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00659269?
The interventions under investigation include: Chemotherapy (DRUG), Multivitamin (MV) (DIETARY_SUPPLEMENT), Multivitamin + Vitamin B12 + Vitamin B6 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00659269?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.